Extranodal Natural Killer (NK)/T-Cell Lymphoma Causing Severe Facial Destruction Refractory to Chemotherapy and Immunotherapy.
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTCL), is a rare, highly aggressive Epstein-Barr virus (EBV)-associated non-Hodgkin lymphoma.
APA
Tiu RA, Garcia JF (2026). Extranodal Natural Killer (NK)/T-Cell Lymphoma Causing Severe Facial Destruction Refractory to Chemotherapy and Immunotherapy.. Cureus, 18(2), e104253. https://doi.org/10.7759/cureus.104253
MLA
Tiu RA, et al.. "Extranodal Natural Killer (NK)/T-Cell Lymphoma Causing Severe Facial Destruction Refractory to Chemotherapy and Immunotherapy.." Cureus, vol. 18, no. 2, 2026, pp. e104253.
PMID
41909399
Abstract
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTCL), is a rare, highly aggressive Epstein-Barr virus (EBV)-associated non-Hodgkin lymphoma. Diagnosis is frequently delayed because early presentation is often non-specific and may mimic many other conditions, including disseminated fungal or atypical bacterial infections, autoimmune conditions such as vasculitis, and other cutaneous malignancies, such as peripheral T-cell lymphomas or melanoma. We present a case of extensive, rapidly progressive and highly destructive necrotic facial and cutaneous lesions, which remained undifferentiated despite initial diagnostic workup, necessitating travel to a quaternary medical center on a medical visa for further evaluation. A thorough workup, including a histopathologic evaluation along with a positive EBV-encoded RNA in situ hybridization, confirmed ENKTCL. The patient's clinical course was marked by extensive local tissue destruction, EBV viremia, severe malnutrition, recurrent episodes of shock, and disease progression despite treatment with pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) and modified dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy and pembrolizumab. This case underscores the diagnostic challenges of ENKTCL and highlights the aggressive clinical course associated with delayed diagnosis and advanced-stage disease, emphasizing the importance of early histopathologic evaluation with EBV testing in patients with progressive necrotic midline lesions.